Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00579982 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder
A Phase 3 study of Mood Disorders, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 97
- Enrollment target
- 18
- Study locations
NCT00579982 is a Phase 3 study of Mood Disorders that has completed, run by GlaxoSmithKline. The registered enrollment target is 97 participants, below the 935-participant average among 39 other Mood Disorders trials with a reported enrollment target (90% lower). The trial reports 18 study locations across 12 states.
The verdict
NCT00579982, a Phase 3 study of Mood Disorders, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 97 participants
- Enrollment target
- 18
- Study locations
Study Summary
To determine the convenience and satisfaction of new orally disintegrating tablet formulation (ODT) of lamictal in subjects with a mood disorder. This was a multicenter, open-label study in participants with a mood disorder, who reported difficulty or discomfort in swallowing the currently marketed IR compressed tablet formulation of lamotrigine and who had a person (such as a spouse, partner, companion, aid, nurse, caregiver, etc) willing to complete a Companion/Caregiver Question. Subjects were switched from the currently marketed lamotrigine IR formulation to a matching dose of lamotrigine IR orally disintegrating tablet (ODT) for 3 weeks to determine convenience and satisfaction.
Conditions Studied
Interventions
- DRUG Lamotrigine
Study Locations (18)
Florida
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Orange City
- GSK Investigational Site - Winter Park
Texas
- GSK Investigational Site - Arlington
- GSK Investigational Site - Houston
- GSK Investigational Site - Houston
California
- GSK Investigational Site - San Diego
- GSK Investigational Site - Santa Ana
Ohio
- GSK Investigational Site - Cincinnati
- GSK Investigational Site - Cleveland
Georgia
- GSK Investigational Site - Marietta
Illinois
- GSK Investigational Site - Fairview Heights
Minnesota
- GSK Investigational Site - Minneapolis
Missouri
- GSK Investigational Site - Saint Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00579982
The ClinicalTrials.gov registry entry for NCT00579982 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 39 other Mood Disorders trials with a reported enrollment target (90% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mood Disorders appearing as the primary indexed condition, and to 1 intervention - of which Lamotrigine is the first listed.
NCT00579982 reports 18 study locations spanning 12 distinct geographic areas - top geographies include Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT00579982 about?
NCT00579982 is a clinical study titled "An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder". To determine the convenience and satisfaction of new orally disintegrating tablet formulation (ODT) of lamictal in subjects with a mood disorder. This was a multicenter, open-label study in participants with a mood disorder, who reported difficulty or discomfort in swallowing the currently marketed ...
What is the current status of trial NCT00579982?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 97 participants. The study started on 2008-01. Estimated completion is 2008-02.
What conditions does trial NCT00579982 study?
This clinical trial studies the following conditions: Mood Disorders.
What interventions are being tested in trial NCT00579982?
The interventions under investigation include: Lamotrigine (DRUG).
Who is sponsoring clinical trial NCT00579982?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00579982 being conducted?
This trial has 18 study locations across California, Florida, Georgia, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mood Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
COMPLETED · Phase 3
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Suicide Specific Rumination in Veterans
RECRUITING · NA
-
Clinical Validation of Samsung Smartwatch
RECRUITING
-
A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences
RECRUITING · NA
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.